Charles Schwab Investment Management Inc. lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 1.8% in the 3rd quarter, according to the company in its ...

Shares of Agios Pharmaceuticals AGIO lost 21% yesterday after management revealed that two thalassemia patients who received its sole-marketed drug Pyrukynd (mitapivat) across two late-stage ...

Finally, Northcape Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $244,000. A number of brokerages have issued reports on ...